At Immuneering, we view partnerships as catalysts for progress. We are actively seeking collaborators who share our vision for establishing a new standard in cancer care, one grounded in rigorous science and a commitment to better outcomes for patients. By working alongside leaders across industry, advocacy, and clinical practice, we are building momentum toward therapies that can make a lasting difference.
In September 2025, Sanofi made a $25 million investment to advance development of Immuneering’s product pipeline through a private placement common stock purchase transaction.
Immuneering and Regeneron Pharmaceuticals established a clinical supply agreement intended to evaluate atebimetinib (IMM-1-104) in combination with Libtayo® in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer (NSCLC).
Immuneering and Lilly established a clinical supply agreement intended to evaluate atebimetinib (IMM-1-104) in combination with olomorasib in patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC).
Guided by our goal to help people with cancer live longer and feel better, we are honored to support PanCAN as a Scientific & Medical Industry Champion.
Immuneering welcomes collaboration with researchers, institutions and organizations aligned with our vision for improving therapeutic durability, tolerability and patient outcomes.
For partnering or business development inquiries, please contact: Harold “E.B.” Brakewood, Chief Business Officer ebrakewood@immuneering.com